Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of The Absolute Bioavailability of TH104

NCT06198686
View directory record Official record
Conditions
Healthy
Interventions
Nalmefene
Drug
Lead sponsor
Tharimmune Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 24, 2026, 7:19 PM EDT
Active, not recruiting Phase 2 Interventional

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

NCT02502786
View directory record Official record
Conditions
Recurrent Osteosarcoma
Interventions
humanized anti-GD2 antibody, GM-CSF
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
13 Months to 40 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren Gel and Oral Diclofenac Sodium

NCT02201238
View directory record Official record
Conditions
Pain
Interventions
Diclofenac sodium, Menthol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals

NCT00308763
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Nicotine Patch, Sustained Release Bupropion
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 45 Years
Enrollment
594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)

NCT01227590
View directory record Official record
Conditions
Drug Interactions, Human Immunodeficiency Virus
Interventions
Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 24, 2026, 7:19 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

NCT03918447
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, ADPKD
Interventions
Bardoxolone methyl oral capsule, Placebo oral capsule
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 70 Years
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
83
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 2 Interventional Results available

Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth

NCT00617240
View directory record Official record
Conditions
Weight Gain
Interventions
metformin, placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of SIAN Nasal Spray in Healthy Adults

NCT05194358
View directory record Official record
Conditions
Cyanide Poisoning
Interventions
Stabilized Isoamyl Nitrite (SIAN)
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)

NCT06699355
View directory record Official record
Conditions
Healthy
Interventions
Enlicitide Decanoate, Atorvastatin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

NCT00001108
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 24, 2026, 7:19 PM EDT
Recruiting Phase 1 Interventional

Excretion of Rivaroxaban in Human Breast Milk

NCT06831474
View directory record Official record
Conditions
Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban, Breastfeeding, Breast Milk Collection
Interventions
Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 1 Interventional Results available

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

NCT03064074
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Fresolimumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 24, 2026, 7:19 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

NCT04980391
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 49 Years · Female only
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 4 Interventional Results available

Atomoxetine in Veterans With Comorbid ADHD/PTSD

NCT02287038
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine 80 MG
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 24, 2026, 7:19 PM EDT
Terminated Phase 2 Interventional Results available

Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates

NCT00986947
View directory record Official record
Conditions
Kidney Failure
Interventions
IVIg and rituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 24, 2026, 7:19 PM EDT
Terminated Early Phase 1 Interventional

19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

NCT03497117
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lung Clearance Index, MRI with PFP
Device · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 24, 2026, 7:19 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

NCT03260868
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

NCT00468585
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine, Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Post-SCI Hypotension

NCT02919917
View directory record Official record
Conditions
Spinal Cord Injury, Autonomic Dysreflexia, Orthostatic Hypotension, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Hypotension, Cerebral Blood Flow, Blood Pressure, Venous Occlusion Plethysmography
Interventions
Midodrine Hydrochloride
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

NCT07487740
View directory record Official record
Conditions
Healthy Participants
Interventions
NAL ER
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 24, 2026, 7:19 PM EDT
Terminated Phase 1 Interventional

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

NCT03905889
View directory record Official record
Conditions
Renal Cell Carcinoma Metastatic
Interventions
Abemaciclib, Sunitinib
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 24, 2026, 7:19 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

NCT02119091
View directory record Official record
Conditions
Cardiac Toxicity
Interventions
Moxifloxacin
Drug
Lead sponsor
Haiyan Li
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

NCT05369390
View directory record Official record
Conditions
Obesity
Interventions
NNC0487-0111 A, NNC0487-0111 B, Placebo B (NNC0487-0111 B), Placebo A (NNC0487-0111 A)
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 24, 2026, 7:19 PM EDT
Completed Phase 3 Interventional Results available

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

NCT03512197
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Midostaurin, Placebo, Chemotherapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 24, 2026, 7:19 PM EDT